These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 26820838)

  • 1. Evaluation of interferon-gamma release assay (T-SPOT.TB(™) ) for diagnosis of tuberculosis infection in rheumatic disease patients.
    Jiang B; Ding H; Zhou L; Chen X; Chen S; Bao C
    Int J Rheum Dis; 2016 Jan; 19(1):38-42. PubMed ID: 26820838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy.
    Behar SM; Shin DS; Maier A; Coblyn J; Helfgott S; Weinblatt ME
    J Rheumatol; 2009 Mar; 36(3):546-51. PubMed ID: 19228655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy.
    Xie X; Chen JW; Li F; Tian J; Gao JS; Zhang D
    Clin Exp Med; 2011 Sep; 11(3):155-61. PubMed ID: 21161670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment.
    Vassilopoulos D; Stamoulis N; Hadziyannis E; Archimandritis AJ
    J Rheumatol; 2008 Jul; 35(7):1271-6. PubMed ID: 18381793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TST, QuantiFERON-TB Gold test and T-SPOT.TB test for detecting latent tuberculosis infection in patients with rheumatic disease prior to anti-TNF therapy.
    Sargın G; Şentürk T; Ceylan E; Telli M; Çildağ S; Doğan H
    Tuberk Toraks; 2018 Jun; 66(2):136-143. PubMed ID: 30246657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.
    Hatzara C; Hadziyannis E; Kandili A; Koutsianas C; Makris A; Georgiopoulos G; Vassilopoulos D
    Ann Rheum Dis; 2015 Oct; 74(10):1848-53. PubMed ID: 24854354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of tuberculin skin testing and T-SPOT.TB for diagnosis of latent and active tuberculosis.
    Simsek H; Alpar S; Ucar N; Aksu F; Ceyhan I; Gözalan A; Cesur S; Ertek M
    Jpn J Infect Dis; 2010 Mar; 63(2):99-102. PubMed ID: 20332570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-sensitive and rapid detection of Mycobacterium tuberculosis infection by IFN-gamma release assay among HIV-infected individuals in BCG-vaccinated area.
    Jiang W; Shao L; Zhang Y; Zhang S; Meng C; Xu Y; Huang L; Wang Y; Wang Y; Weng X; Zhang W
    BMC Immunol; 2009 May; 10():31. PubMed ID: 19476627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an interferon-gamma release assay, T-SPOT.TB, in a population with a low prevalence of tuberculosis.
    Bienek DR; Chang CK
    Int J Tuberc Lung Dis; 2009 Nov; 13(11):1416-21. PubMed ID: 19861016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the usefulness of interferon-gamma release assays and the tuberculin skin test for the detection of latent Mycobacterium tuberculosis infections in Korean rheumatic patients who are candidates for biologic agents.
    Kim JH; Won S; Choi CB; Sung YK; Song GG; Bae SC
    Int J Rheum Dis; 2015 Mar; 18(3):315-22. PubMed ID: 25351815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening for latent tuberculosis infection in patients with chronic inflammatory arthritis: discrepancies between tuberculin skin test and interferon-γ release assay results.
    Costantino F; de Carvalho Bittencourt M; Rat AC; Loeuille D; Dintinger H; Béné MC; Faure G; Chary-Valckenaere I
    J Rheumatol; 2013 Dec; 40(12):1986-93. PubMed ID: 24085550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.
    Escalante P; Kooda KJ; Khan R; Aye SS; Christianakis S; Arkfeld DG; Ehresmann GR; Kort JJ; Jones BE
    Lung; 2015 Feb; 193(1):3-11. PubMed ID: 25318864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tuberculin Skin Test and Quantiferon in BCG Vaccinated, Immunosuppressed Patients with Moderate-to-Severe Inflammatory Bowel Disease.
    Kurti Z; Lovasz BD; Gecse KB; Balint A; Farkas K; Morocza-Szabo A; Gyurcsanyi A; Kristof K; Vegh Z; Gonczi L; Kiss LS; Golovics PA; Lakatos L; Molnar T; Lakatos PL
    J Gastrointestin Liver Dis; 2015 Dec; 24(4):467-72. PubMed ID: 26697573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey.
    Cantini F; Lubrano E; Marchesoni A; Mathieu A; Olivieri I; Salvarani C; Scarpa R; Spadaro A
    Int J Rheum Dis; 2016 Aug; 19(8):799-805. PubMed ID: 26172207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases.
    Pyo J; Cho SK; Kim D; Sung YK
    Korean J Intern Med; 2018 Nov; 33(6):1241-1251. PubMed ID: 29277097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a literature review.
    Chiappini E; Bonsignori F; Accetta G; Boddi V; Galli L; Biggeri A; De Martino M
    Int J Immunopathol Pharmacol; 2012; 25(2):335-43. PubMed ID: 22697065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Borderline QuantiFERON results and the distinction between specific responses and test variability.
    Uzorka JW; Bossink AWJ; Franken WPJ; Thijsen SFT; Leyten EMS; van Haeften AC; Doornenbal G; Boonstra P; Ottenhoff THM; Arend SM
    Tuberculosis (Edinb); 2018 Jul; 111():102-108. PubMed ID: 30029893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosing latent tuberculosis infection in haemodialysis patients: T-cell based assay (T-SPOT.TB) or tuberculin skin test?
    Soysal A; Toprak D; Koc M; Arikan H; Akoglu E; Bakir M
    Nephrol Dial Transplant; 2012 Apr; 27(4):1645-50. PubMed ID: 21931124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay.
    Matulis G; Jüni P; Villiger PM; Gadola SD
    Ann Rheum Dis; 2008 Jan; 67(1):84-90. PubMed ID: 17644549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis of latent tuberculosis infection in bacille Calmette-Guérin vaccinated subjects in China by interferon-gamma ELISpot assay.
    Zhang M; Wang H; Liao M; Chen X; Graner M; Zhu X; Zhang J; Yang Q; Lu H; Zhou B; Chen X
    Int J Tuberc Lung Dis; 2010 Dec; 14(12):1556-63. PubMed ID: 21144240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.